PRCN-829 Gene therapy: This is a patent pending AAV gene therapy designed to be neurotropic in nature. This means that the virus is designed to deliver its’ genetic payload preferentially to neural tissues, such as the brain and spinal cord. This therapy is designed to target several underlying key pathologies associated with ALS. This includes regulation of Complement, neural growth factors and TDP-43. This is the first gene therapy for ALS. It is designed to target multiple genes associated with the complex underlying pathology of ALS.
PRCN-226 Gene therapy: This is a patent pending AAV gene therapy designed to be neurotropic in nature. This gene therapy is designed to protect and enhance dopaminergic neurons for the treatment of Parkinson’s disease.
PRCN-408 Gene therapy: This is a patent pending gene therapy which inhibits the attack of Complement causing the underlying pathology of Macular Degeneration.
PRCN-323 Gene therapy is a neurotropic gene therapy designed to deliver the ABCD1 gene to neural tissue for the treatment of Adrenoleukodystrophy.